To include your compound in the COVID-19 Resource Center, submit it here.

Priority Review for Merck's bezlotoxumab

Merck & Co Inc. (NYSE:MRK) said FDA accepted for filing and granted Priority

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE